Griesinger Georg, Kolibianakis E M, Papanikolaou E G, Diedrich K, Van Steirteghem A, Devroey P, Ejdrup Bredkjaer Helle, Humaidan Peter
Department of Obstetrics and Gynaecology, University Clinic of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany.
Fertil Steril. 2007 Sep;88(3):616-21. doi: 10.1016/j.fertnstert.2006.12.006. Epub 2007 Apr 23.
To report the outcome of frozen-thawed embryo replacement cycles after GnRH-agonist triggering of final oocyte maturation in the collecting cycle with GnRH-antagonist.
Prospective, observational, multicentric clinical study.
Tertiary university-affiliated IVF centers.
PATIENT(S): Patients under observation previously had been recruited into two concurrently performed, independent, randomized controlled trials (comparing hCG with GnRH-agonist for triggering final oocyte maturation in GnRH-antagonist multiple-dose protocols in normal responder patients) encompassing a total of 228 participants. Surplus embryos or oocytes at the pronuclear stage were cryopreserved in 53 patients after hCG administration and 32 patients after GnRH-agonist administration on the basis of patient choice, pronuclear/embryo availability, and local laws.
INTERVENTION(S): Transfer of frozen-thawed embryos.
MAIN OUTCOME MEASURE(S): Live birth rate.
RESULT(S): Thirty-one and 23 patients after administration of hCG and GnRH-agonist, respectively, started a frozen-embryo replacement cycle by September 2005, with 25 and 16 patients eventually undergoing at least one frozen-thawed ET. Live birth rate per ET was 18.5% (95% confidence interval [CI], 8.2-36.7) and 30.0% (95% CI, 14.5-51.9) after hCG and GnRH-agonist triggering, respectively. Cumulative live birth rate per patient starting a frozen-embryo replacement cycle was 16.1% (95% CI, 7.1-32.6) and 26.1% (95% CI, 12.5-46.5) for hCG and GnRH-agonist, respectively.
CONCLUSION(S): The likelihood of live birth in frozen-embryo replacement cycles after GnRH-agonist triggering of final oocyte maturation does not appear to be impaired.
报告在采用GnRH拮抗剂的取卵周期中，使用GnRH激动剂触发最终卵母细胞成熟后进行冻融胚胎移植周期的结果。
前瞻性、观察性、多中心临床研究。
大学附属三级体外受精中心。
之前观察的患者被纳入两项同时进行的独立随机对照试验（比较人绒毛膜促性腺激素与GnRH激动剂在正常反应者患者的GnRH拮抗剂多剂量方案中触发最终卵母细胞成熟），共有228名参与者。根据患者选择、原核/胚胎可用性和当地法律，53名患者在注射hCG后以及32名患者在注射GnRH激动剂后，将原核阶段的多余胚胎或卵母细胞进行了冷冻保存。
冻融胚胎移植。
活产率。
分别有31名和23名患者在注射hCG和GnRH激动剂后，于2005年9月开始了冻融胚胎移植周期，最终分别有25名和16名患者接受了至少一次冻融胚胎移植。hCG和GnRH激动剂触发后，每次胚胎移植的活产率分别为18.5%（95%置信区间[CI]，8.2 - 36.7）和30.0%（95%CI，14.5 - 51.9）。开始冻融胚胎移植周期的每名患者的累积活产率，hCG组为16.1%（95%CI，7.1 - 32.6），GnRH激动剂组为26.1%（95%CI，12.5 - 46.5）。
GnRH激动剂触发最终卵母细胞成熟后进行冻融胚胎移植周期的活产可能性似乎未受损害。
